Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy
Pain, Postoperative, Analgesic Requirement, Stress Response
About this trial
This is an interventional treatment trial for Pain, Postoperative focused on measuring Lignocaine, Laparoscopic cholecystectomy, Pain relief
Eligibility Criteria
Inclusion Criteria:
- Patients planned for elective laparoscopic cholecystectomy in the age group of 20 -60 years belonging to American society of anesthesiologists (ASA)score I-II
Exclusion Criteria:
- Chronic pain diseases other than gall stone disease.
- Use of opioids, steroids, Non steroidal anti inflammatory drugs or alcohol.
- Allergy and contraindication to Lignocaine.
- Conversion to open cholecystectomy.
- Patients who do not comprehend Visual analogue scale (VAS) / patient controlled analgesia (PCA).
Sites / Locations
- Department of Surgery, JIPMER
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Intraperitoneal (IP) group
Intravenous (IV) group
Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.